Clinical efficacy and safety of pemetrexed with or without either Bevacizumab or Pembrolizumab in patients with metastatic nonsquamous non–small cell carcinoma-Reference-Cited by-同舟云学术

Clinical efficacy and safety of pemetrexed with or without either Bevacizumab or Pembrolizumab in patients with metastatic nonsquamous non–small cell carcinoma

Published:2022-04-20 Issue:1 Volume:19 Page:87-95
ISSN:1743-7555
Container-title:Asia-Pacific Journal of Clinical Oncology
language:en
Short-container-title:Asia-Pac J Clncl Oncology

Author:

Kwok Wang Chun¹^ORCID,Cheong Tan Fong²,Chiang Ka Yan¹,Ho James Chung Man¹,Lam David Chi Leung¹,Ip Mary Sau Man¹,Tam Terence Chi Chun¹

Affiliation:

1. Department of Medicine Queen Mary Hospital Pokfulam, Hong Kong Special Administrative Region China

2. Department of Pneumology Centro Hospitalar Conde De Sao Januario Estrada do Visconde de S Januario Macau SAR

Publisher

Wiley

Subject

Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ajco.13658

Reference36 articles.

1. Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy

2. Phase III Trial of Pemetrexed Plus Best Supportive Care Compared With Best Supportive Care in Previously Treated Patients With Advanced Malignant Pleural Mesothelioma

3. Survival without Common Toxicity Criteria Grade 3/4 Toxicity for Pemetrexed Compared with Docetaxel in Previously Treated Patients with Advanced Non-small Cell Lung Cancer (NSCLC): A Risk-Benefit Analysis

4. The Differential Efficacy of Pemetrexed According to NSCLC Histology: A Review of Two Phase III Studies

5. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial